STOCK TITAN
  1. Home
  2. Sec-filings
  3. DCGO
  4. [8-K] DocGo Inc. Reports Material Event

DocGo (NASDAQ: DCGO) shifts board leadership and adds profitability-focused committee

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

DocGo Inc. announced that board member Stephen K. Klasko, MD will step down from the Board and his committee roles, effective at the conclusion of the 2026 Annual Meeting of Stockholders expected on June 16, 2026. His departure is not due to any disagreement with the company.

The Board appointed long-serving independent director Michael Burdiek as independent Chair of the Board, effective at the same time. Jim Travers will replace Dr. Klasko on the Audit and Compliance Committee and the Nominating and Corporate Governance Committee. On April 21, 2026, the Board also formed a special committee of three directors, chaired by Mr. Burdiek, to assist management in identifying corporate efficiencies and cost reduction opportunities to help accelerate profitability.

Positive

  • None.

Negative

  • None.
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Board departure notice date April 17, 2026 Date Stephen K. Klasko notified DocGo of his decision to step down
Effective Time June 16, 2026 Expected date of 2026 Annual Meeting when board changes take effect
Special committee formation date April 21, 2026 Date DocGo’s Board created a special committee on efficiencies and cost reductions
independent Chair of the Board financial
"appointed Michael Burdiek, a long-serving independent member of the Board, as an independent Chair of the Board"
An independent chair of the board is a director who leads the company’s board but is not part of the company’s executive team and has no material ties to its management. Like a neutral referee, this person oversees board meetings, sets agendas, and helps ensure decisions are made in shareholders’ interests rather than to protect insiders. Investors watch for an independent chair as a signal that governance may be stronger, reducing conflicts of interest and improving oversight of strategy, risk and executive pay.
Audit and Compliance Committee financial
"appointed Jim Travers ... as a member of the Board’s Audit and Compliance Committee"
Nominating and Corporate Governance Committee financial
"the Board’s Nominating and Corporate Governance Committee and the Board reassessed the leadership"
A nominating and corporate governance committee is a group within a company's board of directors responsible for selecting and recommending individuals to serve as company leaders, such as directors or executives. They also develop and oversee policies to ensure the company is run fairly, ethically, and transparently. This committee matters to investors because it helps ensure the company is well-managed and guided by qualified, responsible leadership.
special committee financial
"the Board formed a special committee, consisting of Vina Leite, Ira Smedra, and Michael Burdiek"
A special committee is a group of people chosen by an organization to carefully examine a specific issue or problem, often when a decision could have significant consequences. Think of it as a task force brought together to investigate and recommend actions, ensuring that important matters are handled thoroughly and fairly. For investors, this means decisions are made with careful oversight, which can impact the organization's stability and future direction.
emerging growth company regulatory
"Emerging growth company"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
Understanding 8-K Material Events →
0001822359FALSE00018223592026-04-172026-04-17


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
___________________________________

FORM 8-K
___________________________________

CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (date of earliest event reported): April 17, 2026
___________________________________

DOCGO INC.
(Exact name of registrant as specified in its charter)
___________________________________

Delaware
001-39618
85-2515483
(State or other jurisdiction of incorporation or organization)
(Commission File Number)
(I.R.S. Employer Identification No.)
685 Third Avenue, 9th Floor, New York, New York
10017
(Address of principal executive offices)
(Zip Code)
(844) 443-6246
(Registrant's telephone number, including area code)
N/A
(Former name or former address, if changed since last report)
___________________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol
Name of each exchange on which registered
Common stock, par value $0.0001 per share
DCGO
The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 12b-2 of the Exchange Act.

Emerging growth company  ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐


Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On April 17, 2026, Stephen K. Klasko, MD notified DocGo Inc. (the “Company”) of his decision to step down as a member of the Board of Directors (the “Board”) and his other Board and committee positions because he accepted a new significant healthcare leadership role, effective as of the conclusion of the Company’s 2026 Annual Meeting of Stockholders expected to be held on June 16, 2026 (the “Effective Time”). Dr. Klasko’s decision to step down from the Board was not the result of any disagreement with the Company on any matter relating to the Company’s operations, disclosures, policies or practices. The Company is sincerely grateful to Dr. Klasko for his dedicated service on the Board and his contributions to the Company since joining the Board in October 2024.

In connection with Dr. Klasko’s notice of departure from the Board and his Board and committee positions, the Board’s Nominating and Corporate Governance Committee and the Board reassessed the leadership of the Board and appointed Michael Burdiek, a long-serving independent member of the Board, as an independent Chair of the Board, effective as of the Effective Time, with such duties and responsibilities as are customary to the office of Chair of the Board and to be assigned by the Board from time to time. Mr. Burdiek will hold such position until his successor shall have been duly elected and qualified or his earlier resignation, disqualification, death or removal. The Board’s Nominating and Corporate Governance Committee and the Board also reassessed committee compositions and appointed Jim Travers, an independent board member under Nasdaq listing rules, including heightened independence rules applicable to audit committee members, as a member of the Board’s Audit and Compliance Committee and the Nominating and Corporate Governance Committee, in each case to replace Dr. Klasko, effective as of immediately prior to the Effective Time.

In addition, effective immediately, on April 21, 2026, the Board formed a special committee, consisting of Vina Leite, Ira Smedra, and Michael Burdiek, to assist management in identifying corporate efficiencies and cost reduction opportunities in connection with the Company’s goal of accelerating achievement of profitability. Mr. Burdiek will chair this committee.







1

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


DOCGO INC.
By:
/s/ Ely D. Tendler
Name:
Ely D. Tendler
Title:
General Counsel and Secretary

Date: April 21, 2026


2

Source: View Original Filing on SEC EDGAR

FAQ

Why is Stephen K. Klasko leaving the DocGo (DCGO) Board of Directors?

Stephen K. Klasko is stepping down from DocGo’s Board because he accepted a new significant healthcare leadership role. The company states his decision is not due to any disagreement regarding DocGo’s operations, disclosures, policies, or practices, and expresses gratitude for his service since October 2024.

When will Stephen K. Klasko’s departure from DocGo (DCGO) become effective?

Stephen K. Klasko’s departure becomes effective at the conclusion of DocGo’s 2026 Annual Meeting of Stockholders, expected on June 16, 2026. Until then, he continues to serve, after which his Board and committee roles will formally end according to the company’s disclosure.

Who will serve as independent Chair of the Board at DocGo (DCGO)?

DocGo’s Board appointed long-serving independent director Michael Burdiek as independent Chair of the Board. His appointment becomes effective at the same time as Dr. Klasko’s departure, at the conclusion of the 2026 Annual Meeting of Stockholders expected on June 16, 2026.

What new committee responsibilities did DocGo (DCGO) assign to director Jim Travers?

DocGo appointed independent director Jim Travers to its Audit and Compliance Committee and its Nominating and Corporate Governance Committee. He will replace Stephen K. Klasko on both committees, with these changes taking effect immediately prior to the time Klasko’s Board departure becomes effective.

What is the purpose of DocGo’s new special committee formed in April 2026?

On April 21, 2026 DocGo’s Board formed a special committee of directors to assist management in identifying corporate efficiencies and cost reduction opportunities. The company links this work to its goal of accelerating profitability, and appointed Michael Burdiek as chair of this special committee.

Who serves on DocGo’s new special committee focused on efficiencies and cost reduction?

The special committee consists of directors Vina Leite, Ira Smedra, and Michael Burdiek, with Burdiek serving as chair. Formed on April 21, 2026, this committee is tasked with helping management identify corporate efficiencies and cost reduction opportunities to support DocGo’s profitability goals.

Filing Exhibits & Attachments

4 documents

Other Documents